Novo Nordisk Slashes Drug Prices After Eli Lilly Study Hits Stock

Novo Nordisk will slash prices for Ozempic and Wegovy in the USA by up to 50% starting January 2027 following a study showing Eli Lilly's competing drug is more effective.The Danish pharmaceutical giant saw its stock price tumble after cagrisema failed to outperform Eli Lilly's Zepbound in a comparative weight-loss trial.Monthly costs for these GLP-1 medications will drop to $675 to remain competitive as a survey shows 70% of patients are heavily influenced by treatment costs.